Haemocomplettan P (Human Fibrinogen)

Haemocomplettan P is indicated for clinical situations where fibrinogen levels are insufficient to maintain effective hemostasis.

• Congenital fibrinogen deficiency (afibrinogenemia, hypofibrinogenemia) requiring replacement therapy.
• Acquired hypofibrinogenemia associated with massive hemorrhage, liver disease, or disseminated intravascular coagulation.
• Bleeding control during major surgical procedures, including cardiac, hepatic, and orthopedic surgery.
• Management of trauma‑related hemorrhage when rapid fibrinogen supplementation is needed.
• Support of hemostasis in obstetric bleeding such as postpartum hemorrhage.

Adverse reactions reported with Haemocomplettan P are generally related to its plasma origin and the intravenous route of administration.

Common

• Mild fever or chills during or shortly after infusion.
• Transient headache or dizziness.
• Nausea or mild gastrointestinal discomfort.
• Localized infusion site erythema or swelling.

Serious

• Allergic or anaphylactic reactions, including urticaria, bronchospasm, or hypotension.
• Transmission‑related infections (viral or bacterial) despite viral inactivation steps.
• Thromboembolic events such as deep‑vein thrombosis or pulmonary embolism.

Before initiating therapy with Haemocomplettan P, clinicians should evaluate patient history and laboratory parameters to minimize risk.

• Verify fibrinogen plasma levels and coagulation profile prior to administration.
• Assess for known hypersensitivity to human plasma proteins or any component of the formulation.
• Use caution in patients with a history of thromboembolic disease or active clotting disorders.
• Monitor for signs of infection, especially in immunocompromised individuals.
• Adjust dosage in patients with renal or hepatic impairment as recommended by clinical guidelines.
• Avoid use in patients with uncontrolled disseminated intravascular coagulation without specialist input.

Haemocomplettan P may interact with other agents that affect coagulation or immune response, requiring careful management.

Avoid

• Concurrent use of high‑dose anticoagulants (e.g., unfractionated heparin, direct thrombin inhibitors) that could exacerbate bleeding.
• Administration with other plasma‑derived clotting factor concentrates without appropriate monitoring.

Use with caution

• Concomitant antiplatelet drugs (e.g., aspirin, clopidogrel) – monitor platelet function and bleeding time.
• Immunosuppressive therapies – increased risk of infection; observe for febrile reactions.
• Thrombolytic agents – assess risk of paradoxical clot formation.